Niacinamide (nicotinamide)

Vitamin B3 derivative that lowered new non-melanoma skin cancers in one RCT (ONTRAC) of people with a history of them, while they were taking it.

Evidence
Moderate evidenceGRADE certainty: Moderate
Typical dose
The ONTRAC trial used 500 mg twice daily under dermatology care; this is above the EU tolerable upper intake level for nicotinamide
Time to effect
Skin-cancer outcomes assessed over 12 months
Safety
Has documented cautions

Evidence ratings summarise published research on Niacinamide (nicotinamide) in general. They are not a health claim for any product and not advice for any individual. Talk to your doctor before starting anything new, especially if you take medication.

Ask about Niacinamide (nicotinamide)

Interactions

Taking any medication?

Check Niacinamide (nicotinamide) against it.

Why

Niacinamide (nicotinamide) is the amide form of vitamin B3, without the flushing effect of niacin (nicotinic acid). The ONTRAC trial (Chen NEJM 2015, n=386) reported a 23% lower rate of new non-melanoma skin cancers in adults with at least two such cancers in the previous 5 years, on 500 mg twice daily over 12 months, with fewer actinic keratoses. No benefit was seen after stopping. It is a single trial in a high-risk group; it does not show benefit for average-risk people.

How it works

Precursor to NAD+ and NADP+, substrates for poly-ADP-ribose polymerase (PARP)-mediated DNA repair. Restores cellular ATP in UV-stressed keratinocytes.

Expected onset · Skin-cancer outcomes assessed over 12 months, while taking it

How to take

Dosage

The ONTRAC trial used 500 mg twice daily (1 g/day) under dermatology care; this is above the EU tolerable upper intake level for nicotinamide (900 mg/day). Dietary reference intake: 14–16 mg/day.

Timing

With meals, divided

On the label

'Niacinamide' or 'nicotinamide' (not nicotinic acid / niacin).

Studied in

Adults with previous non-melanoma skin cancers (under dermatology guidance); dietary supplementation alternative to flushing niacin.

Safety

The EU upper level for nicotinamide is 900 mg/day for adults; liver toxicity has been reported at doses of several grams a day. Mild GI upset at higher doses. No flushing (distinguishes from nicotinic-acid niacin). Topical: occasional skin irritation in sensitive individuals. Pregnancy: dietary intake is not a documented concern; pharmacological dose data limited.
Loading interactions…

Evidence

At a glance

Chen 2015 N Engl J Med RCT (n=386): in adults with at least two nonmelanoma skin cancers in the previous 5 years, nicotinamide 500 mg twice daily was followed by a 23% lower rate of new nonmelanoma skin cancers than placebo over 12 months (95% CI 4-38). Actinic keratoses were also fewer. No benefit was seen after stopping. Acne and rosacea were not studied.

GRADE certainty: Moderate — rated by Healicus using the GRADE method

Questions people ask

Does Niacinamide (nicotinamide) work?

Chen 2015 N Engl J Med RCT (n=386): in adults with at least two nonmelanoma skin cancers in the previous 5 years, nicotinamide 500 mg twice daily was followed by a 23% lower rate of new nonmelanoma skin cancers than placebo over 12 months (95% CI 4-38). Actinic keratoses were also fewer. No benefit was seen after stopping. Acne and rosacea were not studied. Certainty of the evidence: Moderate, rated by Healicus using the GRADE method.

How is Niacinamide (nicotinamide) taken?

The ONTRAC trial used 500 mg twice daily (1 g/day) under dermatology care; this is above the EU tolerable upper intake level for nicotinamide (900 mg/day). Dietary reference intake: 14–16 mg/day. Timing: With meals, divided. Ranges are those reported in the cited sources, not individual advice; talk to your doctor or pharmacist before starting, especially if you take medication.

Are there interactions or cautions?

The EU upper level for nicotinamide is 900 mg/day for adults; liver toxicity has been reported at doses of several grams a day. Mild GI upset at higher doses. No flushing (distinguishes from nicotinic-acid niacin). Topical: occasional skin irritation in sensitive individuals. Pregnancy: dietary intake is not a documented concern; pharmacological dose data limited. Documented drug and supplement interactions can be looked up in the free interaction reference.

What is the evidence based on?

Sources: Chen et al., NEJM 2015, ONTRAC trial: a phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention; EFSA Reg 432/2012, niacin contributes to normal psychological function, energy-yielding metabolism, nervous system function, reduction of tiredness and fatigue (Niacinamide qualifies for these claims).

One evidence finding a day, like this one: follow Healicus on Threads or Bluesky.